Focalis Bio
Gene therapies for patients with focal refractory epilepsy
Highlights
- New on EvolcAdded 2026-10-31
About Focalis Bio
Focalis Bio is developing gene therapies for focal refractory epilepsy. Its lead investigational programme, EPY201, is intended for targeted delivery to the seizure focus.
The company is based in Canterbury, United Kingdom, and was founded in 2021. In July 2026, it announced a $33 million Series A to support first-in-human Phase 1/2a trials of EPY201.
Product: Develops gene therapy programmes for focal refractory epilepsy, including lead investigational candidate EPY201.
Jobs at Focalis Bio
No open positions listed right now.
Leadership
- Nicolas Koebel · Chief Executive OfficerSource: company website
- Professor Dimitri Kullmann · Chief Scientific Officer and Scientific FounderSource: company website
More biotech & pharma companies
Fortress Diagnostics
In vitro diagnostic tests and reagents for clinical laboratories, healthcare providers and research institutions worldwideNew on EvolcGenedrive PLC
Point-of-care pharmacogenetic tests for NHS clinicians, including antibiotic and antiplatelet treatment kitsNew on EvolcGenomics
Genomic analytics and disease-risk tools for pharmaceutical companies, healthcare providers, employers and individualsRemote-friendlyhameln pharma
Generic injectable medicines for hospitals, pharmacies and palliative care in more than 45 countriesNew on EvolcRemote-friendlyIlc Therapeutics
Develops hybrid interferon therapeutics, with lead candidate Alfacyte in development as an antiviral for RSVNew on EvolcIMU Biosciences
Immune profiling and precision-medicine tools for clinical research, pharmaceutical, biotech and diagnostics organizationsRemote-friendly
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Apache
- CookieYes
- Google Analytics 4